SCHEMBL1809196

SCHEMBL1809196

COC(=O)c1ccc(-c2csc(SCC(=O)NC[C@H]3CN(Cc4ccc(F)c(F)c4)CCO3)n2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.43
MCHR1 Q99705 1/20 0.41
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
RAB9A P51151 6/20 0.40
NPC1 O15118 4/20 0.40
DRD4 P21917 2/20 0.40
HPGD P15428 1/20 0.40
LMNA P02545 2/20 0.40
KDM4E B2RXH2 1/20 0.40
SMN1; SMN2 Q16637 5/20 0.40
TP53 P04637 1/20 0.39
TSHR P16473 1/20 0.39
MCL1 Q07820 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
POLB P06746 1/20 0.39
CCR3 P51677 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
MAPT P10636 1/20 0.38
SIGMAR1 Q99720 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1809194 1.00 ALDH1A1 (0.43) ALDH1A1MCHR1MEN1KMT2ARAB9A
SCHEMBL1807515 0.92 ALDH1A1 (0.46) ALDH1A1MCHR1MEN1KMT2ARAB9A
SCHEMBL1807520 0.92 ALDH1A1 (0.46) ALDH1A1MCHR1MEN1KMT2ARAB9A
SCHEMBL1807254 0.92 CCR3 (0.48) ALDH1A1MCHR1MEN1KMT2ARAB9A
SCHEMBL1807258 0.92 CCR3 (0.48) ALDH1A1MCHR1MEN1KMT2ARAB9A
SCHEMBL1812049 0.91 CCR3 (0.49) ALDH1A1MEN1KMT2ARAB9ANPC1
SCHEMBL1812047 0.91 CCR3 (0.49) ALDH1A1MEN1KMT2ARAB9ANPC1
SCHEMBL1807585 0.84 ALDH1A1 (0.45) ALDH1A1MCHR1MEN1KMT2ARAB9A
SCHEMBL1807583 0.84 ALDH1A1 (0.45) ALDH1A1MCHR1MEN1KMT2ARAB9A
SCHEMBL1807205 0.84 ALDH1A1 (0.50) ALDH1A1MCHR1MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1801108-B9 MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS MITSUBISHI TANABE PHARMA CORP (JP) 2013-11-20 EP disclosed
EP-1801108-B1 MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS MITSUBISHI TANABE PHARMA CORP (JP) 2012-11-14 EP disclosed
US-7935700-B2 Morpholine compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-05-03 US disclosed
US-20070265257-A1 Morpholine Compound MITSUBISHI PHARMA CORPORATION (JP) 2007-11-15 US disclosed
EP-1801108-A1 MORPHOLINE COMPOUND Mitsubishi Pharma Corporation (JP) 2007-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265257-A1 Morpholine Compound CCR3, CCR1, CCR4 ALDH1A1 2661/4885MCHR1 301/4885MEN1 965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.